




Novelion Therapeutics Inc.
Investor Relations Department
887 Great Northern Way, Suite 250
Vancouver V5T 4T5
Canada

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: NVLN

Last Trade:	6.55
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	-0.02  (-0.304%)
Day Range	6.47 - 6.63
52-Week Range	6.41 - 13.80
Volume	28,900

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 12, 2017*
[Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D](#)
- Sep 24, 2017*
[Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day](#)
- Sep 15, 2017*
[Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology](#)
- Sep 11, 2017*
[Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors](#)
- Aug 8, 2017*
[Novelion Therapeutics Reports Second Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

- Mar 30, 2017*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)